Thyroid Eye Disease

Pathophysiology & Risks - Genesis of Graves' Gaze

• Autoimmune: Graves' disease; T-cell mediated.
• Mechanism: TSH-Receptor Antibodies (TRAb) target TSH-R on orbital fibroblasts.
  • Fibroblast activation: ↑ proliferation, differentiation.
  • ↑ Glycosaminoglycan (GAG) production (hyaluronan) → edema.
  • ↑ Adipogenesis (fat cell formation).
• Outcome: Orbital tissue expansion, muscle swelling, inflammation, fibrosis.
• Risk Factors:
  • Smoking (strongest modifiable).
  • Female sex.
  • Genetics (HLA-DR3).
  • Radioiodine therapy (can worsen).

⭐ Key pathogenic mechanism: autoantibodies against TSH receptor (TSH-R) on orbital fibroblasts, leading to glycosaminoglycan accumulation and adipogenesis.

Clinical Features - The Proptotic Profile

• Proptosis (Exophthalmos):
  • Hallmark of TED; bilateral, often asymmetric.
  • Hertel: Normal < 21mm (Caucasians), < 18mm (Asians); inter-eye > 2mm diff. significant.
  • Severity: Mild (21-23mm), Mod. (24-27mm), Severe (>28mm).
• Key Eyelid Signs:
  • Lid Retraction (Dalrymple's): Most common; sclera above limbus.
  • Von Graefe's: Lid lag (downgaze).
  • Stellwag's: Infrequent blinking.
• Soft Tissue:
  • Eyelid/periorbital edema.
  • Conjunctival injection (over recti), chemosis.

⭐ Exophthalmos (proptosis) is the hallmark of TED; lid retraction (Dalrymple's sign) is the most common ocular sign.

Classification - Staging the Stare

NOSPECS Classification (Severity) 📌

• Grades manifestations:

  Class	Finding
  0	No signs/symptoms
  I	Only signs (lid retraction)
  II	Soft tissue
  III	Proptosis (>22mm)
  IV	EOM involvement
  V	Corneal
  VI	Sight loss (Optic Neuropathy)

Clinical Activity Score (CAS) (Activity)

• Active: ≥3/7 or ≥4/10. 1 point/sign.

  Original CAS (7 signs)	Expanded adds (3 signs)
  Pain (spontaneous/gaze)	↑ Proptosis ≥2mm
  Eyelid redness/swelling	↓ Motility ≥8°
  Conj. redness/chemosis	↓ VA ≥1 line
  Inflamed caruncle/plica

⭐ The Clinical Activity Score (CAS) is essential for determining active inflammation and guiding immunosuppressive therapy.

Investigations - Unmasking Orbitopathy

• Thyroid Function Tests (TFTs): TSH, fT3, fT4.
• Autoantibodies:
  • TSH Receptor Antibodies (TRAb) - key diagnostic marker.
  • Anti-Thyroid Peroxidase (Anti-TPO) Antibodies.
• Orbital Imaging:

  ⭐ CT or MRI of the orbits typically reveals fusiform enlargement of extraocular muscle bellies with sparing of the tendons.

  • Assesses Extraocular Muscles (EOMs) (📌 IMSLO: Inferior > Medial > Superior > Lateral > Obliques), optic nerve.
• Functional Tests: Visual fields, color vision (for optic neuropathy).

Management - Calming the Crisis

• Supportive: Smoking cessation, lubricants, selenium.
• Activity: CAS (Clinical Activity Score; active if ≥3/7).
• Severity: NOSPECS / EUGOGO. (📌 NO SPECS: No signs/symptoms, Only signs, Soft tissue, Proptosis, EOM involvement, Corneal, Sight loss).

⭐ Sight-threatening dysthyroid optic neuropathy (DON) is an ophthalmic emergency managed with urgent high-dose systemic corticosteroids (e.g., IV methylprednisolone).

High‑Yield Points - ⚡ Biggest Takeaways

• Thyroid Eye Disease (TED) is the most common cause of proptosis in adults, often bilateral.
• Strongest association with Graves' disease; mediated by TSH receptor antibodies.
• NOSPECS classification is used for severity; optic neuropathy is the most serious complication.
• Classic signs include lid retraction (Dalenrymple's) and lid lag (Von Graefe's).
• Inferior rectus is the most frequently affected extraocular muscle, then medial rectus.
• Treatment aims to manage activity and severity: steroids, radiotherapy, surgical decompression.